The Coalition for Epidemic Preparedness Innovations (CEPI) and aVaxziPen have recently announced their collaboration to enhance needle-free vaccine delivery for equitable global accessibility. This partnership aims to address the challenges of vaccine delivery in low- and middle-income countries, where access to healthcare and vaccination is often limited.<\/p>\n
CEPI is a global partnership that aims to accelerate the development of vaccines against emerging infectious diseases. It was established in 2017 in response to the Ebola outbreak in West Africa, which highlighted the need for a coordinated global response to epidemics. CEPI’s mission is to develop vaccines against known and unknown pathogens that could cause future epidemics.<\/p>\n
aVaxziPen is a medical device company that has developed a needle-free injection system for the delivery of vaccines and other medications. The aVaxziPen system uses a high-pressure jet of liquid to penetrate the skin and deliver the vaccine or medication directly into the muscle tissue. This technology has several advantages over traditional needle-based injections, including reduced pain and anxiety, improved safety, and increased efficiency.<\/p>\n
The collaboration between CEPI and aVaxziPen aims to leverage the benefits of needle-free injection technology to improve vaccine delivery in low- and middle-income countries. One of the main challenges of vaccine delivery in these settings is the lack of trained healthcare workers and the difficulty of transporting and storing vaccines in remote areas. Needle-free injection technology can help overcome these challenges by simplifying the vaccination process and reducing the need for refrigeration.<\/p>\n
The partnership will focus on developing needle-free delivery systems for vaccines against emerging infectious diseases, such as COVID-19, as well as for routine childhood vaccinations. The goal is to increase access to vaccines in low- and middle-income countries and reduce the burden of infectious diseases on vulnerable populations.<\/p>\n
In addition to developing new vaccine delivery systems, CEPI and aVaxziPen will also work to improve existing vaccine delivery methods. This includes developing new formulations of vaccines that are more stable at higher temperatures and can be transported and stored more easily.<\/p>\n
Overall, the collaboration between CEPI and aVaxziPen represents an important step forward in the global effort to improve vaccine delivery and increase access to healthcare in low- and middle-income countries. By leveraging the benefits of needle-free injection technology, this partnership has the potential to transform the way vaccines are delivered and help protect vulnerable populations from infectious diseases.<\/p>\n
The Coalition for Epidemic Preparedness Innovations (CEPI) and aVaxziPen have recently announced their collaboration to enhance needle-free vaccine delivery for equitable global accessibility. This partnership aims to address the challenges of vaccine delivery in low- and middle-income countries, where access to healthcare and vaccination is often limited. CEPI is a global partnership that aims to […]<\/p>\n","protected":false},"author":2,"featured_media":2544665,"menu_order":0,"template":"Default","format":"standard","meta":[],"aiwire-tag":[2441,2012,560,7854,314,3194,3519,12616,789,1573,11,17,132,18,343,6827,20,649,21,790,23,3139,853,7149,29,219,220,370,2170,4805,12354,2314,6747,222,22890,227,686,5483,4262,2342,4828,156,157,1780,867,7107,3176,1502,9709,158,322,4600,233,4266,2190,18009,13972,739,162,1015,50,1016,51,54,1222,1515,55,3685,245,690,1027,475,169,325,21683,57,604,389,170,2216,16608,22962,12312,2946,477,60,61,249,1047,2490,610,2227,1056,176,396,7606,9986,10430,1439,6013,69,9387,298,179,75,2367,78,183,184,23309,185,10236,8079,1261,6906,5,10,7,8,7684,82,13160,299,2971,356,192,5966,2110,2977,6025,411,5885,496,706,11058,1285,22586,8370,3184,778,779,13167,103,781,640,204,10318,108,109,110,207,7180,111,1297,423,3135,8502,13776,516,211,20408,12347,11279,2305,361,9,212,1857,27583,1838,124,1305,3954,6],"aiwire":[31027],"_links":{"self":[{"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/platowire\/2545215"}],"collection":[{"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/platowire"}],"about":[{"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/types\/platowire"}],"author":[{"embeddable":true,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/users\/2"}],"version-history":[{"count":0,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/platowire\/2545215\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/media\/2544665"}],"wp:attachment":[{"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/media?parent=2545215"}],"wp:term":[{"taxonomy":"aiwire-tag","embeddable":true,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/aiwire-tag?post=2545215"},{"taxonomy":"aiwire","embeddable":true,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/aiwire?post=2545215"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}